LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

LifeSpeak Announces First Quarter 2023 Results

May 15, 2023 | Last Trade: C$0.37 0.00 0.00
  • First quarter 2023 revenue of $13.4 million, an increase of 54% compared to the same period in 2022
  • Consolidated Annual Recurring Revenue (or ARR1) as at March 31, 2023 reached $53.3 million, a 4% increase over the same period in 2022; enterprise client ARR increased 14% over the comparable period
  • Total Number of Clients2 increased by 13% to 990 as at March 31, 2023, compared to 873 in the same period in 2022
  • First quarter 2023 Adjusted EBITDA3 of $3.7 million, and Adjusted EBITDA Margin3 of 27%

TORONTO, May 15, 2023 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading whole-person wellbeing solution for employers, health plans and other organizations, announced today its financial and operational results for the three months ended March 31, 2023. All references to dollar values in this press release are in Canadian dollars, unless otherwise indicated.

"The LifeSpeak team continued to gain new customers, diversify its revenue base and further our goal of becoming the world's leading digital wellbeing solution in the first quarter," said Michael Held, CEO and Founder of LifeSpeak. "These operational successes are reflected in our strong first quarter financial results, which include $13.4 million in revenue, $3.7 million in Adjusted EBITDA, and a 27% Adjusted EBITDA Margin. In addition, we made important progress in the first quarter to ensure the financial strength of LifeSpeak going forward by raising additional capital, and renegotiating the terms of our existing debt, to provide us with ample runway to continue to grow our business."

Consolidated Business Highlights for the Three Months Ended March 31, 2023

(All capitalized terms not defined herein shall have the meaning ascribed to them in the Management's Discussion and Analysis for the three months ended March 31, 2023, unless otherwise stated)

  • First quarter 2023 revenue reached $13.4 million, an increase of 54% compared to the same period in 2022, representing a continuing trend of growth in the usage of the Company's platform.
  • Gross Margin for the first quarter 2023 was 90%, an increase compared to Gross Margin of 85% in the comparable period in 2022.
  • ARR of $53.3 million as at March 31, 2023, an increase of 4% over the same period in 2022. Of the $53.3 million of ARR, approximately $44.8 million, or 84%, originated from enterprise clients, an increase of approximately 14% compared to the same period in 2022. Of the $53.3 million of ARR, approximately 66% originated from clients outside of Canada.
  • ARR is reported on a constant currency basis using a 1.30 USD:CAD exchange rate. Given exposure to the US dollar and movement in exchange rates, when adjusting for the exchange rate at the end of the quarter of 1.35 USD:CAD, ARR is approximately $54.7 million.
  • First quarter 2023 Adjusted EBITDA3 of $3.7 million, an increase of $3.3 million compared to the same period in 2022.
  • First quarter 2023 Adjusted EBITDA3 Margin of 27%, an increase when compared to an Adjusted EBITDA3 margin of 4% in the comparable quarter of 2022.
  • First quarter 2023 net loss of $0.4 million, compared to a net loss of $16.2 million in the same period in 2022.
  • Total Number of Clients of 990 as at March 31, 2023, a 15% increase when compared to 862 as at March 31, 2022.
    • Notable enterprise client additions for the first quarter included UMB Financial (U.S.), Cenovus Energy Inc. (Canada), NYU Langone Health (U.S.) BBA Inc. (Canada) and BP Corporation of America, Inc. (U.S.).
    • Embedded solutions client additions continued, with the subsequent to quarter end closing of a U.S. based transaction with Medikeeper, servicing Blue Cross Blue Shield of Massachusetts.
  • Cross-selling initiatives progressed through the first quarter of 2023, with the successful closing of several cross-sale / multi-product opportunities including Manitoba Blue Cross and Health Canada. The Company anticipates continued cross-sale growth in 2023, as net new clients are added with multi-product solutions, and as the current portfolio of client cross-sell opportunities are realized.
  • On March 29, 2023, the Company executed an amendment to the merger agreement in relation to the Wellbeats acquisition in which the value of the contingent consideration was amended to be paid by the Company was set at $1.3 million to settle the contingent amount owing.
  • On March 31, 2023, the Company announced that it entered into a credit agreement with Beedie Investments Ltd. ("Beedie") for a non-revolving term convertible loan in the principal amount of $15.0 million. The Company also announced a second amended and restated credit agreement with its senior lenders, to amend and restate its existing credit agreement to permit the above term loan from Beedie and align terms. Importantly, as part of the terms of the amendment (and among other things), LifeSpeak will have very limited amortization in Fiscal 2023 and significantly reduced obligations in 2024. Under the Beedie Agreement, the Company will not have any principal payments in 2023 and limited cash interest payments through the year.
ARR, Consolidated Net Dollar Retention Rate and Logo Retention Rate Breakdown

ARR was approximately $53.3 as at March 31, 2023, and core enterprise client ARR was approximately $44.8 million. This demonstrates the continued strength of the core enterprise business. The historical and continued pattern of growth in the enterprise client demographic, which comprises approximately 84% of overall ARR as at March 31, 2023, and the diversity of customer, industry, and sector concentration demonstrates the strength of the business and lays a strong foundation for resilience and growth at the core of the LifeSpeak portfolio.

ARR Breakdown

In C$ millions, unless otherwise noted

Q1-2022

Q2-2022

Q3-2022

Q4-2022

Q1-2023

 

YoY
Growth

 

   Total Enterprise ARR

$39.4

$41.0

$43.1

$43.9

$44.8

 

14 %

   Total Embedded Solutions & Other ARR

$11.7

$9.2

$9.1

$9.0

$8.5

 

(28 %)

Total ARR

$51.1

$50.2

$52.2

$52.8

$53.3

 

4 %

 
         

Total ARR (Ex Large Embedded Solutions Client)

$49.6

$50.2

$52.2

$52.8

$53.3

 

8 %

 

Additionally, growth in the Number of Clients continued year-over-year. Total Number of Clients was 990 as at March 31, 2023, or by approximately 15% when compared to the same date in 2022.

Number of Clients

 

Q1-2022

Q2-2022

Q3-2022

Q4-2022

Q1-2023

 

YoY
Growth

   Total Enterprise Clients

847

903

968

983

972

 

15 %

   Total Embedded Solutions Clients

15

18

19

19

18

 

20 %

Total Number of Clients

862

921

987

1,002

990

 

15 %

Consolidated Net Dollar Retention Rate4 for the quarter was 87%, a 5% increase from the same period in 2022, primarily due to the reduced impact from the large, embedded solutions client contract reduction reported during the first quarter of 2022. Net Dollar Retention Rate for enterprise clients was approximately 92% as at March 31, 2023. Though enterprise Net Dollar Retention is slightly lower than the prior period, primarily due to an overall increase in enterprise client churn, churn has been counteracted by cross-sell within the existing enterprise client base. As the cross-sell and up-sell efforts continue, the Company expects Net Dollar Retention Rate to increase as existing clients are sold additional products and services over time.

Logo Retention Rate5 was 83% as at March 31, 2023 compared to 91% for the comparable period in 2022. As retention is measured on a last twelve-month basis, the lower Logo Retention Rate is primarily attributable to the loss of smaller enterprise client logos within the portfolio of customers. New internal initiatives focused on cross-selling products to existing clients, and strong uptake to date in the opportunity to discuss multiproduct solutions with at-risk clients is trending positively, and new logo additions are, on average, larger on an ARR basis than those of logos being lost.

In addition to the continued focus on revenue growth, the Company continues to monitor the cost base of the business and optimize for efficiencies where possible. This focus on costs has allowed the Company to continue to realize cost savings following the acquisitions. In the first quarter of 2023, the Company generated annualized cost savings of approximately $1.4 million, bringing the total annualized savings to approximately $11.1 million. The Company views its current operating state as more than capable of executing on its growth plan into the future.

Financial Results for the Three Months Ended March 31, 2023

Selected Consolidated Financial Information

(in thousands of Canadian dollars)

Three Months Ended March 31,

 

2023

2022

   

Revenue……………………………………………………………………………………………

13,396

8,710

Less:

  

Content development costs………………………………………………………………………

1,322

1,282

Gross Profit…………………………………………………………………………………………

12,074

7,428

Gross Profit Margin (1)

  

Gross Profit Margin…………………………………………………………………………………

90 %

85 %

   

Deduct Expenses:

  

Sales and marketing…………………………………………………………………………………

2,700

3,469

General and administrative………………………………………………………………………….

6,447

6,895

Share-based compensation…………………………………………………………………………

1,466

2,946

Foreign exchange (gain) loss………………………………………………………………………

50

1,694

Amortization and depreciation………………………………………………………………………

4,016

2,417

 

14,679

17,421

   

Loss before undernoted

(2,604)

(9,992)

   

Acquisition and other costs  (2)………………………………………………………………………

-

6,780

Changes in fair value of on contingent consideration…………………………………………......

(3,551)

(694)

Finance expense, net…………………………………………………………………………………

2,195

1,236

   

Loss before income taxes……………………………………………………………………………

(1,249)

(17,315)

Income taxes recovery……………………………………………………………………………….

(894)

(1,110)

   

Net Loss………………………………………………………………………………………………

(354)

(16,205)

   

Earning (loss) per share - basic………………………………………………………………………

(0.01)

(0.33)

Earnings (loss) per share- diluted……………………………………………………………………

(0.01)

(0.33)

   

Non-IFRS Measures and Non-IFRS Ratios

  

EBITDA (3)……………………………………………………………………………………………….

4,963

(13,662)

Adjusted EBITDA (4)……………………………………………………………………………………

3,682

382

Adjusted Net Income (Loss) (5)………………………………………………………………………..

(1,635)

(2,160)

Adjusted earnings (loss) per share – basic (6)…………………………………………………......

(0.03)

(0.04)

Adjusted earnings (loss) per share – diluted (7) …………………………………………………….

(0.03)

(0.04)

   
 

Notes:

(1)

Gross profit margin is calculated as gross profit divided by revenue for the relevant period.

(2)

Restructuring and other costs are costs related to the entry into of the Company's credit agreement and recapitalization distributions and expenses related to the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions.

(3)

"EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(4)

"Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(5)

"Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(6)

"Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(7)

"Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

Conference Call Notification

The Company will hold a conference call to provide a business update on Monday, May 15, 2023, at 8:00 a.m. ET hosted by:

  • Nolan Bederman, Executive Chairman
  • Michael Held, CEO
  • Michael McKenna, CFO

A question-and-answer session will follow the business update.

CONFERENCE CALL DETAILS

DATE:

Monday, May 15, 2023

TIME:

8:00 a.m. ET

DIAL-IN NUMBERS:

1.833.950.0062 or 1.833.470.1428

REFERENCE NUMBER:

917005

This live call is also being webcast and can be accessed by going to: https://events.q4inc.com/attendee/829999542

An archived telephone replay of the call will be available for two weeks by dialing 1.226.828.7578 or 1.866.813.9403 and entering access code 815016.    

Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators

LifeSpeak supplements its results of operations determined in accordance with IFRS with certain non-IFRS financial measures, non-IFRS ratios and key performance indicators that the Company believes are useful to investors, lenders and others in assessing its performance and which highlight trends its core business that may not otherwise be apparent when relying solely on IFRS measures. LifeSpeak management also uses non-IFRS measures, non-IFRS ratios and key performance indicators for purposes of comparison to prior periods, to prepare annual operating budgets, for the development of future projections and earnings growth prospects, to measure the profitability of ongoing operations and in analyzing our financial condition, business performance and trends. As such, these measures and indicators are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective, including how it evaluates its financial performance and how it manages its capital structure. LifeSpeak also believes that securities analysts, investors and other interested parties frequently use these non-IFRS measures, non-IFRS ratios and key performance indicators in the evaluation of issuers. These non-IFRS measures, non-IFRS ratios and key performance indicators are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may include or exclude certain items as compared to similar IFRS measures, and such measures may not be comparable to similarly-titled measures reported by other companies. Accordingly, these measures and indicators should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.

Non-IFRS Measures, Non-IFRS Ratios and Reconciliation of Non-IFRS Measures

The Company uses non-IFRS measures, including "EBITDA", "Adjusted EBITDA", "Adjusted Net Income (Loss)", and the non-IFRS ratios, including "Adjusted earnings (loss) per share – basic", "Adjusted earnings (loss) per share – diluted" and "Adjusted EBITDA Margin". This press release also makes reference to "Annual Recurring Revenue" or "ARR", "Net Dollar Retention Rate", "Number of Clients" and "Logo Retention Rate", which are key performance indicators used in our industry.

EBITDA and Adjusted EBITDA 

"EBITDA" is defined as net profit or loss before income tax expenses, finance costs and depreciation and amortization.

"Adjusted EBITDA" is defined as EBITDA before non-recurring restructuring and other costs related to the entry into of the Company's credit agreement and recapitalization distributions, expenses related to the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters, cost and expenses related to the Company's acquisitions, synergies realized in connection with the acquisitions, share-based compensation, foreign exchange loss (gain) and shareholders distributions. These non-recurring costs are independent events which are non-recurring in nature and incurred over several financial periods.

"Adjusted EBITDA Margin" is calculated as Adjusted EBITDA divided by revenue for the relevant period.

Selected Consolidated Financial Information

(In thousands of Canadian dollars)

 

Three Months Ended March 31,

  

2023

2022

Net income (loss)………………………………………………………………………………………...

 

(354)

(16,205)

Add:

   

Amortization and depreciation expense…………………………………………………………........

 

4,016

2,417

Finance expense…………………………………………………………………………………………

 

2,195

1,236

Income tax expense (recovery) ………………………………………………………………………

 

(894)

(1,110)

EBITDA (1) ………………………………………………………………………………………………

 

4,963

(13,662)

Add:

   

Acquisition and other costs (2) ……………………………………………………………………….

 

-

6,780

Share-based compensation……………………………………………………………………………

 

1,466

2,946

Foreign exchange loss (gain) ………………………………………………………………………..

 

50

1,694

Changes in fair value of contingent consideration ……………………………………………......

 

(3,551)

(694)

Synergies realized (3) …………………………………………………………………………………..

 

237

720

Additional one-time costs (4) …………………………………………………………………………

 

517

2,598

Adjusted EBITDA (5) ……………………………………………………………………………………

 

3,682

382

Adjusted EBITDA Margin (6) …………………………………………………………………………

 

27 %

4 %

  
 

Notes:

(1)

"EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(2)

Restructuring and other costs are costs related to the entry into of the Company's credit agreement and recapitalization distributions and expenses related to the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions.

(3)

Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions.

(4)

One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition.

(5)

"Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(6)

"Adjusted EBITDA Margin" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

Adjusted Net Income (Loss) / Adjusted Earnings (Loss)

"Adjusted Net Income (Loss)" is defined as net income (loss) before non-recurring restructuring and other costs related to the entry of the Company's credit agreement and recapitalization distributions, expenses related to the investment by the Institutional Investors and costs and expenses in connection with the Company's IPO and related matters, cost and expenses related to the Company's acquisitions, synergies realized in connection with the acquisitions, share-based compensation, foreign exchange loss (gain). These non-recurring costs are independent events which are non-recurring in nature and incurred over several financial periods.

"Adjusted earnings (loss) per share – basic" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – basic for the relevant period.

"Adjusted earnings (loss) per share – diluted" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – diluted for the relevant period.

Selected Consolidated Financial Information

(In thousands of Canadian dollars)

 

Three Months Ended December 31,

  

2023

2022

Net income (loss) ………………………………………………………………………………………

 

(354)

(16,205)

Add:

   

Acquisition and other costs (1) ………………………………………………………………………

 

-

6,780

Share-based compensation…………………………………………………………………………..

 

1,466

2,946

Foreign exchange loss (gain) …………………………………………………………………………

 

50

1,694

Changes in fair value of contingent consideration……………………………………………….

 

(3,551)

(694)

Synergies realized (2) ……………………………………………………………………………………

 

237

720

Additional one-time costs (3) ………………………………………………………………………….

 

517

2,598

Adjusted Net Income (Loss) (4) ……………………………………………………………………….

 

(1,635)

(2,160)

Adjusted earnings per share – basic (5) …………………………………………………………….

 

(0.03)

(0.04)

Adjusted earnings per share – diluted (6)…………………………………………………………....

 

(0.03)

(0.04)

  
 

Notes:

(1)

Restructuring and other costs are costs related to the entry into of the Company's credit agreement and recapitalization distributions and expenses related to the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions.

(2)

Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions.

(3)

One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition.

(4)

"Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures and Key Performance Indicators."

(5)

"Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

(6)

"Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators".

Key Performance Indicators

Annual Recurring Revenue

"Annual Recurring Revenue" or "ARR" is equal to the annualized value of contracted recurring revenue from all clients of our platform at the date being measured. Contracted recurring revenue is revenue generated from clients who are, as of the date being measured, party to contracts with LifeSpeak. Such revenue is annualized by: (i) in the case where a contract was in existence for the entire month, multiplying recognized revenue in the calendar month of the date measured by 12; and (ii) in the case where a contract was entered into mid-month, extrapolating recognized revenue at the date measured for the entire calendar month, and then multiplying by 12. Contract lengths typically range from one to three years and, based on our past experience, the vast majority of clients renew their contracts upon expiry. ARR is mainly comprised of revenue from enterprise and embedded solutions and includes revenue from small business and ancillary services (comprised of portals, kits and events purchased by our existing clients or distributed through our channel partners). ARR provides a consolidated measure by which we can monitor the longer-term trends in our business.

"enterprise client ARR" is ARR at a particular date attributable to enterprise clients.

Net Dollar Retention Rate

"Net Dollar Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the ARR from enterprise and embedded solutions attributable to that cohort at the end of the period, by the ARR from enterprise and embedded solutions attributable to that cohort at the beginning of the period. Net Dollar Retention Rate provides a consolidated measure by which we can monitor the percentage of recurring ARR retained from existing clients.

Number of Clients

"Number of Clients" is defined as the number of clients at the end of any particular period as the number of enterprise clients and clients of our embedded solutions for which the term of services has not ended, or with which the Company is negotiating contract renewal and which meet a minimum revenue threshold.

Logo Retention Rate

"Logo Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the Number of Clients from that cohort at the end of the period, by the Number of Clients from that cohort at the beginning of the period. Logo Retention Rate provides a consolidated measure by which the Company can monitor the percentage of contracted clients retained every year.

About LifeSpeak Inc.

LifeSpeak is the leading whole-person-wellbeing platform for employers and other organizations that brings together digital education with human support. Our suite of wellbeing products allows organizations to provide best-in-class content and expertise that scales, meeting each individual wherever they are on their personal wellbeing journeys. As the parent company to LIFT Digital, ALAViDA Health, Torchlight, and Wellbeats, LifeSpeak provides in-depth expertise across mental health, wellness, physical fitness, substance use, and caregiving. With more than 30 years of collective experience working directly with Fortune 500 companies, government agencies, insurance providers, and others across the globe, we understand the complexities of addressing wellbeing within organizations, which is why our digital and data-driven approach provides insights that uncover gaps in wellbeing at the organizational level, ultimately enhancing performance outcomes. To learn more, follow LifeSpeak on LinkedIn (http://www.linkedin.com/company/lifespeak-inc), or visit www.LifeSpeak.com.

Forward-Looking Information

This press release may contain "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information may relate to the Company's future business, financial outlook and anticipated events or results and may include information regarding the Company's financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, and the Company's plans and objectives. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Particularly, information regarding the Company's expectations of future results, revenue growth, ARR, EBITDA, adjusted EBITDA margin, adjusted EBITDA, adjusted Net Income (Loss), adjusted Earnings (Loss), Number of Clients, Net Dollar Retention Rate, Logo Retention Rate, performance, synergies, achievements, prospects, industry trends, advancement of its strategy and acceleration of its growth, the use of proceeds of the loan advance from the credit agreement with Beedie, amortization or opportunities, including for cross-selling, or the markets in which the Company operates is forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding possible future events or circumstances.

This forward-looking information and other forward-looking information are based on opinions, estimates and assumptions in light of the Company's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. These opinions, estimates and assumptions include, but are not limited to, the following: the Company's ability to build its market share and enter new geographies; the total available market for its products; the Company's ability to retain key personnel; the Company's ability to maintain and expand geographic scope; the Company's ability to execute on its expansion plans; the Company's ability to continue investing in infrastructure to support its growth and brand recognition; the Company's ability to continue maintaining and enhancing its technological infrastructure and functionality of its platform; the Company's ability to obtain financing on acceptable terms; the Company's ability to effectively integrate its recent acquisitions; the Company's ability to generate sufficient cash to deleverage, the impact of competition; the changes and trends in the Company's industry or the global economy; and changes in laws, rules, regulations, and global standards.

The risks and uncertainties that may affect forward-looking statements include, among others: performance of the market sectors that the Company serves; general market performance including capital market conditions and availability and cost of credit; foreign currency and exchange risk; impact of factors such as increased pricing pressure and possible margin compression; the regulatory and tax environment; that expected cost and revenue synergies are not realized within the expected timeframe or at all; that revenue, ARR, EBITDA margin and cash flow expectations are not met for any number of reasons; political, labour or supplier disruptions; that our clients face recessionary pressures, and other risks detailed from time to time in the Company's filings with Canadian provincial securities regulators, including the risk factors which are described in greater detail under "Risk Factors" in the Company's annual information form for the fiscal year ended 2022. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not currently known to the Company or that the Company currently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

Accordingly, prospective investors should not place undue reliance on forward-looking information. The forward-looking information contained in this press release represents the Company's expectations as of the date of this press release (or as the date it is otherwise stated to be made) and is subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements. Prospective investors should read this entire press release and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of an investment in the Company.

1 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "ARR" 

2 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "Number of Clients"

3 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "Adjusted EBITDA" and "Adjusted EBITDA Margin" 

4 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition, "Net Dollar Retention Rate".

5 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition, "Logo Retention Rate".

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB